Preliminary Agenda
Revised Feb.23, 2023
International Conference on Subarachnoid Hemorrhage
Duke University, Department of Neurosurgery
|
Friday, June 16, 2023 |
|
|---|---|
| 1:00-1:10 pm | Introductions and opening remarks, Washington Duke Inn |
| 1:10-1:30 | John Zhang, MD, PhD: History of aneurysmal SAH research |
| 1:30-3:30 |
Oral Abstract Session with Junior Scientists and Clinician-Scientists Tatsat Patel, PhD: Novel deep-learning methods for cerebral vessel and aneurysm segmentation Redi Rashmani, MD: ABT263 senolysis for the prevention of intracranial aneurysm rupture in mice Freddie Ewbank, PhD: (TBA) Kerry Poppenberg, PhD: Analyzing epigenetic landscapes around IA haplotypes to understand genetic risk Sricharan Veeturi, PhD: Quantitative imaging biomarkers for cerebral aneurysm risk stratification |
| 3:30-3:50 | Break |
| 3:50-4:10 | Yong Jiang, MD, PhD: Disequilibrium of metabolic homeostasis after SAH |
| 4:10-4:30 | Hiroki Uchikawa, MD,PhD: Pretreatment with clodronate improved neurofunction involving in inhibition of cerebral blood flow reduction in rat SAH |
| 4:30-4:50 | Gang Chen, MD, PhD: How the neuro-glial network responds to subarachnoid hemorrhage |
| 4:50-5:10 | Rebecca Heinz, MD: Toll-like receptor4-pathway in neuroinflammation after SAH – possible future targets |
| 5:10-5:30 | Ulf C. Schneider, MD: The role of extracellular RNA for microglia activation after SAH |
| 5:30-5:50 | Sepideh Amin-Hanjani, MD: AHA/ASA guidelines form management of SAH |
| 5:50-6:10 | Jens P. Dreier, MD, PhD: Brain Discharge - 1 |
| 6:30-8:30. | Cocktails and hors d'oeuvres, Washington Duke Hotel |
|
Saturday, June 17 |
|
|---|---|
| 6:45-7:40 am | Breakfast |
| Biomarkers of Subarachnoid Hemorrhage | |
| 7:40-8:00 am | Emanuela Keller, MD: Prediction and detection of delayed cerebral ischemia in high-grade SAH patients |
| 8:00-8:20 am | H Alex Choi, MD: Biomarkers of cerebral edema after subarachnoid hemorrhage |
| 8:20-8:40 am | Sherry Hsiang-Yi Chou, MD: MicroRNA Endotypes in SAH |
| 8:40-9:00 am | George Kwok Chu Wong, MD: miRNA Predictors after aneurysmal subarachnoid hemorrhage |
| 9:00-9:20 am | Elisa Cudrado-Godia, MD, PhD: GWAS and vasospasm and DCI |
| 9:20-9:40 am | Diederik Bulters, MD: GWAS of outcome after SAH |
| 9:40--10:00 am | Robert Lock MacDonald, MD: A machine-learning approach to definition and thresholds for intervention for DCI |
| 10:00-10:15 am | Mahmud Bossa-Basha, MD: Shortcomings of conventional aneurysm imaging and the value of advanced imaging for aneurysm and vasospasm management |
| 10:15-10:40 | Break |
| Novel Therapeutics 1 | |
| 10:40-11:00 am | Ian Galea, MD: Hemoglobin and haptoglobin: From basic science to clinical implications for SAH |
| 11:00-11:20 am | Michael Hugelshofer, MD: CSF-Hemoglobin after aSAH: biomarker and therapeutic target |
| 11:20-11:35 am | Jin Pyeong Jeon MD, PhD: Beyond genetics: Haptoglobin alpha isoform expression and outcome after SAH |
| 11:35-11:50 am | Spiros Blackburn, MD: Haptoglobin genetics and outcome after SAH |
| 11:50-12:00 pm | Soham Bandyopadhyay, MBBS: Research priorities in haptoglobin clinical translation: A Delphi-based consensus |
| 12:00 -12:50 pm | Lunch |
| Novel Therapeutics 2 | |
| 12:50-1:10 pm | Thierno Madjou Bah, PhD: GPR39 as a therapeutic target in SAH |
| 1:10-1:30 pm | Stephan Mayer, MD: Taming the autonomic storm after SAH |
| 1:30-1:50 pm | Daniel Laskowitz, MD: Selective NMDA inhibitors in high-risk aSAH: Neuroprotection revisited |
| 1:50-2:30 |
Lifetime Achievement Award James Torner, PhD: What have previous clinical trials taught us? |
| Inflammation and SAH 1 | |
| 2:30-2:50 pm | Tomoki Hashimoto, MD: Translational research of intracranial aneurysm |
| 2:50-3:10 pm | Devin McBride, PhD: Role of platelets after SAH |
| 3:10-3:40 | Break |
| Inflammation and SAH 2 | |
| 3:40-3:55 pm | Aaron M. Gusdon, MD: Systemic metabolic alterations after aneurysmal subarachnoid hemorrhage |
| 3:55-4:10 pm | Naoki Kaneko, MD, PhD: How do endothelial cells respond to flow in cerebral aneurysms? Bridging computational flow dynamics and endothelial biology |
| 4:10-4:25 pm | Wonjae Lee, PhD: Microfluidic neurovascular unit model for precision medicine |
| 4:25-4:40 pm | Moinak Banerjee, MD; Genetics, epigenetics and metabolomics of iSAH: an Indian perspective |
| SAH Recovery | |
| 4:40-4:55 pm | Wayne Fang, MD: The road to recovery post aSAH |
| 4:55-5:10 pm | Sheila A. Alexander, PhD, RN: Omics of recovery from aSAH |
| 6:00-9:00 pm | Dinner, JB Duke Hotel |
|
Sunday, June 18 |
|
|---|---|
| 6:40-7:35 am | Breakfast |
| Clinical Trials 1 | |
| 7:40-7:55 am | Isabel Charlotte Hostettler, MD, PhD: Influenceable factors in aneurysmal subarachnoid hemorrhage: Is there a light at the end of the tunnel after all? |
| 7:55-8:10 am | Mervyn D.I. Vergouwen, MD, PhD: Complement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Hemorrhage (CLASH): a randomized controlled phase IIa clinical trial |
| 8:10-8:25 am | Philippe Bijenga, MD, PhD: How to compensate for bias when using health data based on Bayes’ theorem |
| 8:25-8:40 am | Alejandro A. Rabinstein, MD: Antifibrinolytics in aSAH: Case closed? |
| 8:40-8:55 am | David Hasan, MD: iSPASM-1 |
| 8:55-9:10 am | Jose I Suarez, MD: Variance in care of SAH patients |
| 9:10-9:25 am | Anthony Delaney, MBBS, MSc, PhD: The future of clinical trials for aSAH: Where should we stand? |
| 9:25-9:40 am | Jose Javier Provencio, MD: TBA |
| 9:40-9:55 am | Stefan Wolf, MD: TBA |
| 9:55-10:20 am | Break |
| Clinical Trials 2 | |
| 10:20-10:35 am | Chris Anderson, PhD: Development of a core outcome set for patients with aneurysmal subarachnoid hemorrhage |
| 10:35-10:50 am | Emily Fitzgerald, PhD: A systematic review assessing the association between method of outcome assessment and reported outcomes in SAH patients |
| 10:50-11:05 am | Lachlan Donaldson MBBS (Hons) MPhil FCICM: The reported incidence of cerebral arterial vasospasm following aneurysmal subarachnoid hemorrhage is highly variable, and a consensus definition is required: A systematic review and meta-analysis |
| 11:05-11:20 am | Shane English,MD: SAHaRA trial |
| 11:20-11:35 am | Ketan R. Bulsara, MD, and Rock Chen, MD: The intra-arterial vasospasm trial |
| 11:35-11:50 am | Michael Veldeman, MD, PhD: Intra-arterial spasmolysis for the treatment of delayed cerebral ischemia: What do we achieve by making vessels wide? |
| 12:00 am-12:40 pm | Lunch |
| Clinical Trials 3 | |
| 12:40-12:55 pm | Hemant Bhagat, MD: aSAH and anesthesia: Current understanding |
| 12:55-1:10 pm | Behnam Rezai Jahromi, MD: Vasospasm and shunt dependency with active CSF exchange |
| 1:10-1:25 pm | Miriam Treggiari, MD, PhD: Cervical sympathetic blockade to manage cerebral vasospasm |
| 1:25-1:40 pm | Christine Buckley: The need for center of excellence designation to improve patient outcome |
| 1:40-2:20 pm |
iSAH 2023 Honored Guest Speaker Gabriel Rinkle, MD: Insights on future research in SAH |
| Unruptured Aneurysms 1 | |
| 2:20-2:35 pm | Yuichi Murayama, MD: Computational fluid dynamic analysis of the initiation of cerebral aneurysms: Experimental and human studies |
| 2:35-2:50 pm | Aichi Chien, PhD: Longitudinal changes in human brain aneurysms |
| 2:50-3:05 pm | Anne M. Robertson, PhD: Engineering and materials science mechanobiology of cerebral aneurysm blebs |
| 3:05-3:30 | Break |
| Unruptured Aneurysms 2 | |
| 3:30-3:45 pm | Edgar A Samaniego, MD, MSc: What can we learn from determining the enhancement of the aneurysm wall? |
| 3:45-4:00 pm | Vincent M. Tutino, PhD: Circulating molecular signatures of Intracranial aneurysm |
| 4:00-4:15 pm | Nima Etminan, MD: Risk factor modification as a therapeutic target in unruptured intracranial aneurysms |
| 4:15-4:30 pm | Soichiro Fujimura, PhD: AI for prediction of unruptured intracranial aneurysms (Japan, US, European multicenter study) |
| 4:30-4:45 pm | Jingfeng (JJ) Jiang, PhD: Artificial intelligence-augmented computational hemodynamic analysis of intracranial aneurysms |
| 4:45-5:00 pm | Closing remarks and announcement of iSAH 2025 in Hong Kong |